What is the GARDASIL Access Program?
Merck pledged to donate at least 3 million doses of GARDASIL, its quadrivalent HPV vaccine, to qualifying organizations and institutions in eligible lowest income countries, where approximately 80% of the
world’s cervical cancer cases occur.
This newsletter aims to update interested parties on the status of the GARDASIL Access Program, share operational experiences and lessons learned by participants, and contribute to the public body of knowledge regarding HPV vaccination and successful child and adolescent immunization models in developing countries.
Following the November 2009 meeting of the GARDASIL Access Program Advisory Board, four new applicants were approved. To date, 18 organizations and institutions in 17 eligible countries have been
approved to participate in the program.
What has been achieved to date?
By December 2009:
• Approval of 18 applications proposing HPV vaccination projects, in 17 countries (Bhutan, Bolivia, Cambodia, Cameroon, Georgia, Ghana, Haiti, India, Kenya, Lesotho, Moldova, Nepal, Nicaragua, Papua New Guinea,
Tanzania, Uganda, Uzbekistan)
• 496,000 doses of GARDASIL pledged for donation, enough to
vaccinate over 165,000 beneficiaries (a full series consists of three doses administered over a six-month period)
By March 2010:
• 302,400 doses of GARDASIL shipped to 9 of the 18 participants approved to date, enough to vaccinate over 100,000 beneficiaries
• 3 participants had completed at least one full HPV vaccination series, and 6 participants were at various stages of implementation in their respective HPVvaccination projects